Question
Do compounding pharmacies need recall insurance?
Short answer
503A traditional compounding rarely needs dedicated recall coverage because patient-specific dispensing limits aggregate recall exposure. 503B outsourcing facilities almost always need it as a hospital purchase contract condition, typically at $3M-$10M first-party limits.
503A: recall coverage usually not required
503A traditional compounding operates on a patient-specific prescription model, so any recall event affects a defined small population of patients with traceable dispensing records.
Hospital purchase contracts do not flow to 503A scope because 503A scope precludes non-patient-specific supply.
A products policy sublimit or a recall extension endorsement is usually sufficient at this scope.
503B: dedicated recall coverage almost always required
503B outsourcing facilities operate on a non-patient-specific supply model, and recall events can affect thousands of patients across multiple hospital systems simultaneously.
Hospital purchase contracts almost universally require dedicated recall coverage, sized $3M-$10M first-party, on a stand-alone form (not as a products sublimit).
The 503B regulatory framework includes adverse event reporting under FD&C 503B(b)(5)(B), which creates faster recall escalation than the 503A pathway.
Primary sources
Sources and references
This answer draws on the following regulatory, statutory, and standards-body sources. Coverage availability and program structure also depend on carrier appetite and underwriter discretion not captured by these sources.
- FDA Section 503A Compounding Pharmacy Guidancehttps://www.fda.gov/drugs/human-drug-compounding/section-503a-compounding-pharmacy
- FDA Section 503B Outsourcing Facility Registrationhttps://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
Related practice areas
Insurance clauses in this area
Related questions
Have a more specific question?
A specialist will reach out by the end of the day.
Request a free coverage review